OBJECTIVE: Amyotrophic lateral sclerosis (ALS) is a heterogeneous disease with a complex etiology that lacks biomarkers predicting disease progression. The objective of this study was to use longitudinal cerebrospinal fluid (CSF) samples to identify biomarkers that distinguish fast progression (FP) from slow progression (SP) and assess their temporal response. METHODS: We utilized mass spectrometry (MS)-based proteomics to identify candidate biomarkers using longitudinal CSF from a discovery cohort of SP and FP ALS patients. Immunoassays were used to quantify and validate levels of the top biomarkers. A state-transition mathematical model was created using the longitudinal MS data that also predicted FP versus SP. RESULTS: We identified a total of 1148 proteins in the CSF of all ALS patients. Pathway analysis determined enrichment of pathways related to complement and coagulation cascades in FPs and synaptogenesis and glucose metabolism in SPs. Longitudinal analysis revealed a panel of 59 candidate markers that could segregate FP and SP ALS. Based on multivariate analysis, we identified three biomarkers (F12, RBP4, and SERPINA4) as top candidates that segregate ALS based on rate of disease progression. These proteins were validated in the discovery and a separate validation cohort. Our state-transition model determined that the overall variance of the proteome over time was predictive of the disease progression rate. INTERPRETATION: We identified pathways and protein biomarkers that distinguish rate of ALS disease progression. A mathematical model of the CSF proteome determined that the change in entropy of the proteome over time was predictive of FP versus SP.

Cancer and Cell Biology Division Translational Genomics Research Institute Phoenix Arizona 85004 USA

Department of Computational and Quantitative Medicine Beckman Research Institute City of Hope Medical Center Duarte California 91010 USA

Department of Hematologic Malignances Translational Science Gehr Family Center for Leukemia Research Beckman Research Institute City of Hope Medical Center Duarte California 91010 USA

Department of Translational Neuroscience Barrow Neurological Institute Phoenix Arizona 85013 USA

Integrated Mass Spectrometry City of Hope Comprehensive Cancer Center Duarte California 19050 USA

International Clinical Research Center St Anne's University Hospital Brno Czech Republic

Zobrazit více v PubMed

Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942‐955. PubMed

Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539(7628):197‐206. PubMed PMC

Verde F, Steinacker P, Weishaupt JH, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(2):157‐164. PubMed

Sun Q, Zhao X, Li S, et al. CSF neurofilament light chain elevation predicts ALS severity and progression. Front Neurology. 2020;11:919. doi:10.3389/fneur.2020.00919 PubMed DOI PMC

Ganesalingam J, An J, Bowser R, Andersen PM, Shaw CE. pNfH is a promising biomarker for ALS. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2013;14(2):146‐149. PubMed

Cudkowicz ME, Lindborg SR, Goyal NA, et al. A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle Nerve. 2022;65(3):291‐302. PubMed PMC

Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1–2 trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109‐119. PubMed

Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2022;387:1099‐1110. PubMed

Poesen K, Van Damme P. Diagnostic and prognostic performance of neurofilaments in ALS. Front Neurol. 2019;9:1167. doi:10.3389/fneur.2018.01167 PubMed DOI PMC

Huang F, Zhu Y, Hsiao‐Nakamoto J, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7(7):1103‐1116. PubMed PMC

Gagliardi D, Meneri M, Saccomanno D, Bresolin N, Comi GP, Corti S. Diagnostic and prognostic role of blood and cerebrospinal fluid and blood neurofilaments in amyotrophic lateral sclerosis: a review of the literature. Int J Mol Sci. 2019;20(17):4152. doi:10.3390/ijms20174152 PubMed DOI PMC

Lu CH, MacDonald‐Wallis C, Gray E, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84(22):2247‐2257. PubMed PMC

Milligan C, Atassi N, Babu S, et al. Tocilizumab is safe and tolerable and reduces C‐reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients. Muscle Nerve. 2021;64(3):309‐320. PubMed PMC

Perez‐Riverol Y, Csordas A, Bai J, et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 2019;47(D1):D442‐D450. PubMed PMC

Zhang X, Smits AH, van Tilburg GB, Ovaa H, Huber W, Vermeulen M. Proteome‐wide identification of ubiquitin interactions using UbIA‐MS. Nat Protoc. 2018;13(3):530‐550. PubMed

Rohart F, Gautier B, Singh A, Le Cao KA. mixOmics: An R package for 'omics feature selection and multiple data integration. PLoS Comput Biol. 2017;13(11):e1005752. PubMed PMC

Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein‐protein association networks with increased coverage, supporting functional discovery in genome‐wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607‐D613. PubMed PMC

Shi L, Westerhuis JA, Rosen J, Landberg R, Brunius C. Variable selection and validation in multivariate modelling. Bioinformatics. 2019;35(6):972‐980. PubMed PMC

Robin X, Turck N, Hainard A, et al. pROC: an open‐source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77. PubMed PMC

Gao W, Kannan S, Oh S, Viswanath P. Estimating mutual information for discrete‐continuous mixtures. Adv Neural Inf Process Syst. 2017;December;5987‐5998.

Vu LT, An J, Kovalik T, Gendron T, Petrucelli L, Bowser R. Cross‐sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes. J Neurol Neurosurg Psychiatry. 2020;91:350‐358. PubMed PMC

Uhlenbeck GE, Ornstein LS. On the theory of the Brownian motion. Phys Rev. 1930;36(5):823‐841.

Rockne RC, Branciamore S, Qi J, et al. State‐transition analysis of time‐sequential gene expression identifies critical points that predict development of acute myeloid leukemia. Cancer Res. 2020;80(15):3157‐3169. PubMed PMC

Zubiri I, Lombardi V, Bremang M, et al. Tissue‐enhanced plasma proteomic analysis for disease stratification in amyotrophic lateral sclerosis. Mol Neurodegener. 2018;13(1):60. PubMed PMC

Reiber H. Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source‐related dynamics. Restor Neurol Neurosci. 2003;21(3–4):79‐96. PubMed

Thompson AG, Gray E, Charles PD, et al. Network analysis of the CSF proteome characterizes convergent pathways of cellular dysfunction in ALS. Front Neurosci. 2021;15:642324. PubMed PMC

Miyazaki K, Ohta Y, Nagai M, et al. Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis. J Neurosci Res. 2011;89(5):718‐728. PubMed

Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood‐brain barrier: from physiology to disease and Back. Physiol Rev. 2019;99(1):21‐78. PubMed PMC

Winkler EA, Sengillo JD, Sagare AP, et al. Blood‐spinal cord barrier disruption contributes to early motor‐neuron degeneration in ALS‐model mice. Proc Natl Acad Sci U S A. 2014;111(11):E1035‐E1042. PubMed PMC

Zhong Z, Deane R, Ali Z, et al. ALS‐causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci. 2008;11(4):420‐422. PubMed PMC

Garbuzova‐Davis S, Hernandez‐Ontiveros DG, Rodrigues MC, et al. Impaired blood‐brain/spinal cord barrier in ALS patients. Brain Res. 2012;1469:114‐128. PubMed

Henkel JS, Beers DR, Wen S, Bowser R, Appel SH. Decreased mRNA expression of tight junction proteins in lumbar spinal cords of patients with ALS. Neurology. 2009;72(18):1614‐1616. PubMed

Winkler EA, Sengillo JD, Sullivan JS, Henkel JS, Appel SH, Zlokovic BV. Blood‐spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125(1):111‐120. PubMed PMC

Saul J, Hutchins E, Reiman R, et al. Global alterations to the choroid plexus blood‐CSF barrier in amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2020;8(1):92. PubMed PMC

Joardar A, Manzo E, Zarnescu DC. Metabolic dysregulation in amyotrophic lateral sclerosis: challenges and opportunities. Curr Genet Med Rep. 2017;5(2):108‐114. PubMed PMC

Ravera S, Torazza C, Bonifacino T, et al. Altered glucose catabolism in the presynaptic and perisynaptic compartments of SOD1G93A mouse spinal cord and motor cortex indicates that mitochondria are the site of bioenergetic imbalance in ALS. J Neurochem. 2019;151(3):336‐350. PubMed

Gray E, Larkin JR, Claridge TD, et al. The longitudinal cerebrospinal fluid metabolomic profile of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7–8):456‐463. PubMed PMC

Lawton KA, Cudkowicz ME, Brown MV, et al. Biochemical alterations associated with ALS. Amyotroph Lateral Scler. 2012;13(1):110‐118. PubMed

Manzo E, Lorenzini I, Barrameda D, et al. Glycolysis upregulation is neuroprotective as a compensatory mechanism in ALS. Elife. 2019;8:e45114. PubMed PMC

Chen Y, Liu XH, Wu JJ, et al. Proteomic analysis of cerebrospinal fluid in amyotrophic lateral sclerosis. Exp Ther Med. 2016;11(6):2095‐2106. PubMed PMC

Garranzo‐Asensio M, San Segundo‐Acosta P, Martínez‐Useros J, et al. Identification of prefrontal cortex protein alterations in Alzheimer's disease. Oncotarget. 2018;9(13):10847‐10867. PubMed PMC

Chao J, Guo Y, Li P, Chao L. Role of kallistatin treatment in aging and cancer by modulating miR‐34a and miR‐21 expression. Oxid Med Cell Longev. 2017;2017:5025610. doi:10.1155/2017/5025610 PubMed DOI PMC

Chao J, Guo Y, Chao L. Protective role of endogenous kallistatin in vascular injury and senescence by inhibiting oxidative stress and inflammation. Oxid Med Cell Longev. 2018;2018:4138560. doi:10.1155/2018/4138560 PubMed DOI PMC

Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate‐taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919‐930. PubMed PMC

Salomon‐Zimri S, Pushett A, Russek‐Blum N, et al. Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2023;24(3–4):263‐271. PubMed